Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Non-Small Cell Lunch Cancer × NVP-BKM120 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 20 Neoplasm Metastasis 14 Carcinoma, Non-Small-Cell Lung 6 Triple Negative Breast Neoplasms 4 Ovarian Neoplasms 4 Glioblastoma 4 Endometrial Neoplasms 4 Colorectal Neoplasms 4 Recurrence 3 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Neoplasms 3 Hereditary Sensory and Autonomic Neuropathies 3 Brain Neoplasms 3 Solid Tumors 2 Melanoma 2 Lymphoma, Mantle-Cell 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Follicular 2 Lymphoma 2 Lung Neoplasms 2 Leukemia, Myeloid, Acute 2 Head and Neck Neoplasms 2 Esophageal Neoplasms 2 Unspecified Adult Solid Tumor, Protocol Specific 1 Thyroid Neoplasms 1 Skin Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pre-menopausal Breast Cancer 1 Non-Small Cell Lunch Cancer 1

Interventions

Paclitaxel 1 NVP-BKM120 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01820325 2018-10-11

BASALT-2

Novartis

Phase 1 Terminated

Non-Small Cell Lunch Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡